Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01650948 · ClinicalTrials.gov registry record
Genetic Load and Phenotype in Aggressive AMD
A clinical trial of Age-related Macular Degeneration, sponsored by Sequenom.
- Completed
- Registry status
- 100
- Enrollment target
- 3
- Study locations
NCT01650948 is a study of Age-related Macular Degeneration that has completed, run by Sequenom. The registered enrollment target is 100 participants, below the 1,506-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01650948, a study of Age-related Macular Degeneration, has completed, sponsored by Sequenom.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 3
- Study locations
Study Summary
Patients with AMD will provide cheek cell samples to determine if their is a correlation between genotype (DNA markers) and phenotype (the type of AMD the patient has).
Conditions Studied
Interventions
- DEVICE RetnaGene AMD LDT
Study Locations (3)
California
- Pacific Eye Associates - San Francisco
Kentucky
- Retina Associates of Kentucky - Lexington
Tennessee
- Tennessee Retina - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01650948
The ClinicalTrials.gov registry entry for NCT01650948 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,506-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (93% lower). The listed sponsor is Sequenom, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which RetnaGene AMD LDT is the first listed.
NCT01650948 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Kentucky, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01650948 about?
NCT01650948 is a clinical study titled "Genetic Load and Phenotype in Aggressive AMD". Patients with AMD will provide cheek cell samples to determine if their is a correlation between genotype (DNA markers) and phenotype (the type of AMD the patient has).
What is the current status of trial NCT01650948?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2012-07. Estimated completion is 2013-12.
What conditions does trial NCT01650948 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT01650948?
The interventions under investigation include: RetnaGene AMD LDT (DEVICE).
Who is sponsoring clinical trial NCT01650948?
This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01650948 being conducted?
This trial has 3 study locations across California, Kentucky, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
High Resolution Retinal Imaging
RECRUITING
-
Visual Remapping to Aid Reading With Field Loss
RECRUITING · NA
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
Effects of Goji vs. Fiber on Macular Degeneration
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.